Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Clinical trial NCT03333616 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03333616
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Genitourinary Cancer Adrenocortical Carcinoma Non-urothelial Bladder Non-urothelial Upper Tract Penile Cancer Non-adenocarcinoma Prostate Cancer Refractory Germ-cell High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma

Start date: 2017-12-28
Primary completion: 2026-12-30
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.